Related Experiment Video
Updated: May 26, 2026
Rapid Production of Recombinant Human SLFN14 Ribonuclease and Stoichiometric Analysis by Mass Photometry
Published on: February 20, 2026
Rational design and evaluation of mammalian ribonuclease cytotoxins
Jo E Lomax1, Chelcie H Eller, Ronald T Raines
1Graduate Program in Cellular & Molecular Biology, University of Wisconsin-Madison, Madison, Wisconsin, USA.
Abstract:
Mammalian pancreatic-type ribonucleases (ptRNases) comprise an enzyme family that is remarkably well suited for therapeutic exploitation. ptRNases are robust and prodigious catalysts of RNA cleavage that can naturally access the cytosol. Instilling cytotoxic activity requires endowing them with the ability to evade a cytosolic inhibitor protein while retaining other key attributes. These efforts have informed our understanding of ptRNase-based cytotoxins, as well as the action of protein-based drugs with cytosolic targets. Here, we address the most pressing problems encountered in the design of cytotoxic ptRNases, along with potential solutions. In addition, we describe assays that can be used to evaluate a successful design in vitro, in cellulo, and in vivo. The emerging information validates the continuing development of ptRNases as chemotherapeutic agents.
Insights
Mammalian pancreatic-type ribonucleases (ptRNases) are promising cytotoxic agents. Researchers are developing strategies to overcome challenges in designing effective ptRNase-based cancer therapies and evaluating their efficacy.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Mammalian pancreatic-type ribonucleases (ptRNases) are enzymes capable of RNA cleavage.
- These enzymes can naturally enter the cytosol, making them suitable for therapeutic applications.
- Cytotoxic activity requires ptRNases to bypass cytosolic inhibitors while maintaining essential functions.
Purpose of the Study:
- To address key challenges in designing cytotoxic ptRNases for cancer therapy.
- To propose solutions for overcoming design obstacles.
- To describe methods for evaluating the efficacy of designed ptRNases.
Main Methods:
- Review of existing literature on ptRNase design and function.
- Analysis of strategies for evading cytosolic inhibitors.
- Description of in vitro, in cellulo, and in vivo assays for evaluation.
Main Results:
- Identification of critical problems in cytotoxic ptRNase design.
- Proposal of potential solutions and design strategies.
- Validation of assays for assessing ptRNase efficacy.
Conclusions:
- The development of ptRNase-based chemotherapeutics is a viable and progressing field.
- Overcoming inhibitor evasion is crucial for ptRNase cytotoxicity.
- Comprehensive evaluation methods support the advancement of ptRNase cancer therapies.
More Related Videos
09:03A Simple Fluorescence-based Reporter Assay to Identify Cellular Components Required for Ricin Toxin A Chain (RTA) Trafficking in Yeast
Published on: December 15, 2017
07:23Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
